Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Breast 31Genitourinary 14Gastrointestinal 9Gynecologic 6Other hematologic neoplasm 4Head & Neck 4Endocrine 3Sarcoma 2Lymphoid 2Dermatologic 2CNS 2Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Myeloid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Follicular 1Lymphoma 1

Interventions

Rituximab 1371Cyclophosphamide 1297Vincristine 662Doxorubicin 583Etoposide 525Prednisone 505Cytarabine 481fludarabine 462Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 255ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 228Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × High-Energy Shock Waves × Lymphoid × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00987428 2025-11-20

EEPAB2

Assistance Publique - Hôpitaux de Paris

Phase NA Terminated
27 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡